These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Vancomycin-associated renal dysfunction: where are we now? Carreno JJ; Kenney RM; Lomaestro B Pharmacotherapy; 2014 Dec; 34(12):1259-68. PubMed ID: 25220436 [TBL] [Abstract][Full Text] [Related]
24. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. McKamy S; Hernandez E; Jahng M; Moriwaki T; Deveikis A; Le J J Pediatr; 2011 Mar; 158(3):422-6. PubMed ID: 20888013 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Burgess LD; Drew RH Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041 [TBL] [Abstract][Full Text] [Related]
26. Vancomycin Therapeutic Targets and Nephrotoxicity in Critically Ill Children With Cancer. Seixas GT; Araujo OR; Silva DC; Arduini RG; Petrilli AS J Pediatr Hematol Oncol; 2016 Mar; 38(2):e56-62. PubMed ID: 26558810 [TBL] [Abstract][Full Text] [Related]
27. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity. Rostas SE; Kubiak DW; Calderwood MS Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573 [TBL] [Abstract][Full Text] [Related]
29. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639 [TBL] [Abstract][Full Text] [Related]
30. Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy. Knoderer CA; Gritzman AL; Nichols KR; Wilson AC Ann Pharmacother; 2015 Oct; 49(10):1113-9. PubMed ID: 26160972 [TBL] [Abstract][Full Text] [Related]
31. Impact of an Antimicrobial Stewardship Program on Patient Safety in Veterans Prescribed Vancomycin. Fodero KE; Horey AL; Krajewski MP; Ruh CA; Sellick JA; Mergenhagen KA Clin Ther; 2016 Mar; 38(3):494-502. PubMed ID: 26831569 [TBL] [Abstract][Full Text] [Related]
32. Addition of Vancomycin to Cefazolin Prophylaxis Is Associated With Acute Kidney Injury After Primary Joint Arthroplasty. Courtney PM; Melnic CM; Zimmer Z; Anari J; Lee GC Clin Orthop Relat Res; 2015 Jul; 473(7):2197-203. PubMed ID: 25421958 [TBL] [Abstract][Full Text] [Related]
33. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Constance JE; Balch AH; Stockmann C; Linakis MW; Korgenski EK; Roberts JK; Ward RM; Sherwin CM; Spigarelli MG Arch Dis Child Fetal Neonatal Ed; 2016 May; 101(3):F236-43. PubMed ID: 26400103 [TBL] [Abstract][Full Text] [Related]
34. Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships. Scheetz MH; Pais GM; Lodise TP; Tong SYC; Davis JS; O'Donnell JN; Liu J; Neely M; Prozialeck WC; Lamar PC; Rhodes NJ; Holland T; Avedissian SN Antimicrob Agents Chemother; 2021 Sep; 65(10):e0106021. PubMed ID: 34339278 [TBL] [Abstract][Full Text] [Related]
36. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients. Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798 [TBL] [Abstract][Full Text] [Related]
37. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221 [TBL] [Abstract][Full Text] [Related]
38. Vancomycin Should Be Considered a Nephrotoxic Antimicrobial Agent: PRO. Murphy ME; Barreto EF Kidney360; 2022 Sep; 3(9):1484-1487. PubMed ID: 36245668 [No Abstract] [Full Text] [Related]
39. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. Al Yami MS J Infect Public Health; 2017; 10(6):770-773. PubMed ID: 28209320 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]